Voxtalisib
- Generic Name
- Voxtalisib
- Drug Type
- Small Molecule
- Chemical Formula
- C13H14N6O
- CAS Number
- 934493-76-2
- Unique Ingredient Identifier
- CVL1685GPH
- Background
Voxtalisib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Breast Cancer, among others.
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 65
- Registration Number
- NCT01936363
- Locations
- ๐ช๐ธ
Research site, Valencia, Spain
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 49
- Registration Number
- NCT01596270
- Locations
- ๐บ๐ธ
Investigational Site Number 840001, Detroit, Michigan, United States
๐บ๐ธInvestigational Site Number 840002, New Brunswick, New Jersey, United States
๐บ๐ธInvestigational Site Number 840003, Dallas, Texas, United States
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
- First Posted Date
- 2012-04-27
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 61
- Registration Number
- NCT01587040
- Locations
- ๐บ๐ธ
Investigational Site Number 840104, Fort Myers, Florida, United States
๐บ๐ธInvestigational Site Number 840008, Los Angeles, California, United States
๐บ๐ธInvestigational Site Number 840006, Augusta, Georgia, United States
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
- Conditions
- Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 37
- Registration Number
- NCT01410513
- Locations
- ๐บ๐ธ
Investigational Site Number 840006, Augusta, Georgia, United States
๐บ๐ธInvestigational Site Number 840002, Charleston, South Carolina, United States
๐บ๐ธInvestigational Site Number 840004, Aurora, Colorado, United States
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 167
- Registration Number
- NCT01403636
- Locations
- ๐ง๐ช
Investigational Site Number 056003, Bruxelles, Belgium
๐บ๐ธInvestigational Site Number 840001, Philadelphia, Pennsylvania, United States
๐บ๐ธInvestigational Site Number 840002, Morgantown, West Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.